Biocontrol

Search documents
Biotalys Reports Half-Year 2025 Financial Results and Business Highlights
Globenewswire· 2025-09-18 05:00
Press release - regulated informationGhent, Belgium, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Substantial progress in both the U.S. and Europe in the regulatory review of Biotalys’ first candidate biofungicide EVOCA™*Patent protection for EVOCA in Brazil and China, and for a BioFun-6 lead candidate in the U.S.Strategic partnership with AgroFresh to expand into post-harvest segmentLeadership team expanded with proven industry executives Cash and cash equivalents amounted to €15.7 million as of the end of June 202 ...
Publication of transparency notification
Globenewswire· 2025-06-16 16:00
Core Viewpoint - Biotalys NV has received a transparency notification from Sofinnova Partners SAS regarding its shareholding, indicating that Sofinnova now holds 9.93% of Biotalys' voting rights as of June 11, 2025 [1][2]. Company Information - Biotalys is an Agricultural Technology (AgTech) company focused on developing protein-based biocontrol solutions aimed at sustainable crop protection, providing alternatives to conventional chemical pesticides [5]. - The company utilizes its AGROBODY™ technology platform to create a diverse pipeline of product candidates targeting key crop pests and diseases throughout the agricultural value chain [5]. - Founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology), Biotalys has been listed on Euronext Brussels since July 2021 and is based in Ghent, Belgium [5]. Shareholding Details - As of June 11, 2025, Sofinnova Partners SAS holds 3,719,820 shares of Biotalys, which corresponds to 9.93% of the total voting rights [2][6]. - The previous notification indicated that Sofinnova held 4,226,962 voting rights, showing a decrease in their holdings [3]. - The threshold crossed by Sofinnova was 10%, with a total denominator of 37,470,062 shares [6].
Biotalys Reports Progress in the Regulatory Review of EVOCA in both US and EU
Globenewswire· 2025-06-11 05:00
Core Insights - Biotalys is making significant progress in the regulatory approval of its first protein-based biocontrol product, EVOCA™, in both the United States and Europe [2][3][4] Regulatory Developments - The US Environmental Protection Agency (EPA) is expected to complete the scientific review of EVOCA's dossier by the end of summer 2025, with a regulatory decision projected by September 30, 2025 [3] - In Europe, the Dutch authorities have provided positive evaluations of EVOCA's regulatory dossier, classifying its active ingredient as low risk, which is crucial for its approval process [4][5] Product Information - EVOCA™ is designed to control fungal diseases such as Botrytis and powdery mildew, offering biodegradable solutions for fruit and vegetable growers [6] - The product is based on Biotalys' AGROBODY™ technology platform, which has the potential to develop additional protein-based biocontrol solutions [6][8] Future Outlook - A regulatory decision in the European Union is anticipated in the second half of 2026, contingent upon the provision of additional data during the peer review phase [5] - The approval of EVOCA would represent a major milestone for Biotalys and validate its innovative technology platform [6]